The role of indacaterol for chronic obstructive pulmonary disease (COPD)

Indacaterol is the first long-acting β2-agonist (LABAs) approved for the treatment of chronic obstructive pulmonary disease (COPD) that allows for once-daily (OD) administration. It is rapidly acting, with an onset of action in 5 minutes, like salbutamol and formoterol but with a sustained bronchodi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Formato: Artigo
Idioma:en
Publicado em: Pioneer Bioscience Publishing Company 2013
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3755680/
https://ncbi.nlm.nih.gov/pubmed/23991316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2013.07.35
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
id pubmed-3755680
record_format dspace
institution US National Library of Medicine
collection PubMed Central
language en
format Article
topic Review Article
spellingShingle Review Article
The role of indacaterol for chronic obstructive pulmonary disease (COPD)
topic_facet Review Article
description Indacaterol is the first long-acting β2-agonist (LABAs) approved for the treatment of chronic obstructive pulmonary disease (COPD) that allows for once-daily (OD) administration. It is rapidly acting, with an onset of action in 5 minutes, like salbutamol and formoterol but with a sustained bronchodilator effect, that last for 24 hours, like tiotropium. In long-term clinical studies (12 weeks to 1 year) in patients with moderate to severe COPD, OD indacaterol 150 or 300 μg improved lung function (primary endpoint) significantly more than placebo, and improvements were significantly greater than twice-daily formoterol 12 μg or salmeterol 50 μg, and noninferior to OD tiotropium bromide 18 μg. Indacaterol was well tolerated at all doses and with a good overall safety profile. Cost-utility analyses show that indacaterol 150 μg has lower total costs and better outcomes than tiotropium and salmeterol. These findings suggest that indacaterol can be considered a first choice drug in the treatment of the patient with mild/moderate stable COPD. However, in people with COPD who remain symptomatic on treatment with indacaterol, adding a long-acting muscarinic antagonist (LAMA) is the preferable option. In any case, it is advisable to combine indacaterol with a OD inhaled corticosteroid (ICS), such as mometasone furoate or ciclesonide, in patients with low FEV1, and, in those patients who have many symptoms and a high risk of exacerbations, to combine it with a LAMA and a OD ICS.
author_sort Cazzola, Mario
title The role of indacaterol for chronic obstructive pulmonary disease (COPD)
title_short The role of indacaterol for chronic obstructive pulmonary disease (COPD)
title_full The role of indacaterol for chronic obstructive pulmonary disease (COPD)
title_fullStr The role of indacaterol for chronic obstructive pulmonary disease (COPD)
title_full_unstemmed The role of indacaterol for chronic obstructive pulmonary disease (COPD)
title_sort role of indacaterol for chronic obstructive pulmonary disease (copd)
publisher Pioneer Bioscience Publishing Company
publisher_facet Pioneer Bioscience Publishing Company
publishDate 2013
url https://ncbi.nlm.nih.gov/pmc/articles/PMC3755680/
https://ncbi.nlm.nih.gov/pubmed/23991316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2013.07.35
_version_ 1872505321151266816

Registros relacionados